Lina Steinrud Mørch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lina Steinrud Mørch has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ellen Løkkegaard
Department of Gynaecology and Obstetrics, Nordsjællands Hospital, Hillerød, Denmark
7 shared publications Øjvind Lidegaard
Rigshospitalet, Copenhagen, Denmark
5 shared publications- Anne Helms Andreasen
Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
3 shared publications - Susanne Kriiger Kjaer
Unit of Virus, Lifestyle and Genes Danish Cancer Institute Copenhagen Denmark
3 shared publications Niels Keiding
Department of Biostatistics, Institute of Public Health, University of Copenhagen, Copenhagen, Denmark
2 shared publications- Anne Tjønneland
Danish Cancer Institute, Copenhagen, Denmark
1 shared publication
Latest Publications
- 29 March 2018
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 378 (13) , 1263-1266
Contemporary Hormonal Contraception and the Risk of Breast Cancer
To the Editor: Mørch et al. (Dec. 7 issue)1 have reignited concerns about the safety of a range of contemporary hormonal contraceptive methods. Since a diagnosis of cancer is frequently interpreted as a death sentence, it is unfortunate that the authors did not report their findings on the effects of hormonal contraceptives on either the rate of death from breast cancer or the rate of death from any cause. This is a particular concern because multiple high-quality studies2-4 have shown that the use of hormonal contraceptives is associated with a significantly lower risk of death from any cause than the . . .
- 29 March 2018
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 378 (13) , 1263-1266
Contemporary Hormonal Contraception and the Risk of Breast Cancer
To the Editor: Mørch et al. (Dec. 7 issue)1 have reignited concerns about the safety of a range of contemporary hormonal contraceptive methods. Since a diagnosis of cancer is frequently interpreted as a death sentence, it is unfortunate that the authors did not report their findings on the effects of hormonal contraceptives on either the rate of death from breast cancer or the rate of death from any cause. This is a particular concern because multiple high-quality studies2-4 have shown that the use of hormonal contraceptives is associated with a significantly lower risk of death from any cause than the . . .
- Top Cited Papers
- 7 December 2017
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 377 (23) , 2228-2239
Contemporary Hormonal Contraception and the Risk of Breast Cancer
Little is known about whether contemporary hormonal contraception is associated with an increased risk of breast cancer.
- 7 December 2017
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 377 (23) , 2228-2239
Top Cited PapersContemporary Hormonal Contraception and the Risk of Breast Cancer
Little is known about whether contemporary hormonal contraception is associated with an increased risk of breast cancer.
- 12 January 2016
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 31 (5) , 481-489
The influence of hormone therapies on colon and rectal cancer
Exogenous sex hormones seem to play a role in colorectal carcinogenesis. Little is known about the influence of different types or durations of postmenopausal hormone therapy (HT) on colorectal cancer risk. A nationwide cohort of women 50–79 years old without previous cancer (n = 1,006,219) were followed 1995–2009. Information on HT exposures was from the National Prescription Register and updated daily, while information on colon (n = 8377) and rectal cancers (n = 4742) were from the National Cancer Registry. Potential confounders were obtained from other national registers. Poisson regression analyses with 5-year age bands included hormone exposures as time-dependent covariates. Use of estrogen-only therapy and combined therapy were associated with decreased risks of colon cancer (adjusted incidence rate ratio 0.77, 95 % confidence interval 0.68–0.86 and 0.88, 0.80–0.96) and rectal cancer (0.83, 0.72–0.96 and 0.89, 0.80–1.00), compared to never users. Transdermal estrogen-only therapy implied more protection than oral administration, while no significant influence was found of regimen, progestin type, nor of tibolone. The benefit of HT was stronger for long-term hormone users; and hormone users were at lower risk of advanced stage of colorectal cancer, which seems supportive for a causal association between hormone therapy and colorectal cancer.
- 12 January 2016
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 31 (5) , 481-489
The influence of hormone therapies on colon and rectal cancer
Exogenous sex hormones seem to play a role in colorectal carcinogenesis. Little is known about the influence of different types or durations of postmenopausal hormone therapy (HT) on colorectal cancer risk. A nationwide cohort of women 50–79 years old without previous cancer (n = 1,006,219) were followed 1995–2009. Information on HT exposures was from the National Prescription Register and updated daily, while information on colon (n = 8377) and rectal cancers (n = 4742) were from the National Cancer Registry. Potential confounders were obtained from other national registers. Poisson regression analyses with 5-year age bands included hormone exposures as time-dependent covariates. Use of estrogen-only therapy and combined therapy were associated with decreased risks of colon cancer (adjusted incidence rate ratio 0.77, 95 % confidence interval 0.68–0.86 and 0.88, 0.80–0.96) and rectal cancer (0.83, 0.72–0.96 and 0.89, 0.80–1.00), compared to never users. Transdermal estrogen-only therapy implied more protection than oral administration, while no significant influence was found of regimen, progestin type, nor of tibolone. The benefit of HT was stronger for long-term hormone users; and hormone users were at lower risk of advanced stage of colorectal cancer, which seems supportive for a causal association between hormone therapy and colorectal cancer.
- Open Access
- 30 September 2015
- Published by Wiley in International Journal of Cancer
- Vol. 138 (6) , 1506-1515
The influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study
The influence of hormone therapy (HT) on risk for endometrial cancer is still casting which type of HT the clinicians recommend. It is unrevealed if HT has a differential influence on Type I versus Type II endometrial tumors, and little is known about the influence of, e.g., different routes of administration and about the influence of tibolone. We followed all Danish women aged 50–79 years without previous cancer or hysterectomy (n = 914,595) during 1995–2009. From the National Prescription Register, we computed HT exposures as time‐dependent covariates. Incident endometrial cancers (n = 6,202) were identified from the National Cancer Registry: 4,972 Type I tumors and 500 Type II tumors. Incidence rate ratios (RRs) and 95% confidence intervals (Cls) were estimated by Poisson regression. Compared with women never on HT, the RR of endometrial cancer was increased with conjugated estrogen: 4.27 (1.92–9.52), nonconjugated estrogen: 2.00 (1.87–2.13), long cycle combined therapy: 2.89 (2.27–3.67), cyclic combined therapy: 2.06 (1.88–2.27), tibolone 3.56 (2.94–4.32), transdermal estrogen: 2.77 (2.12–3.62) and vaginal estrogen: 1.96 (1.77–2.17), but not with continuous combined therapy: 1.02 (0.87–1.20). In contrast, the risk of Type II tumors appeared decreased with continuous combined therapy: 0.45 (0.20–1.01), and estrogen therapy implied a nonsignificantly altered risk of 1.43 (0.85–2.41). Our findings support that continuous combined therapy is risk free for Type I tumors, while all other hormone therapies increase risk. In contrast, Type II endometrial cancer was less convincingly associated with hormone use, and continuous combined therapy appeared to decrease the risk.
- 30 September 2015
- Published by Wiley in International Journal of Cancer
- Vol. 138 (6) , 1506-1515
Open AccessThe influence of hormone therapies on type I and II endometrial cancer: A nationwide cohort study
The influence of hormone therapy (HT) on risk for endometrial cancer is still casting which type of HT the clinicians recommend. It is unrevealed if HT has a differential influence on Type I versus Type II endometrial tumors, and little is known about the influence of, e.g., different routes of administration and about the influence of tibolone. We followed all Danish women aged 50–79 years without previous cancer or hysterectomy (n = 914,595) during 1995–2009. From the National Prescription Register, we computed HT exposures as time‐dependent covariates. Incident endometrial cancers (n = 6,202) were identified from the National Cancer Registry: 4,972 Type I tumors and 500 Type II tumors. Incidence rate ratios (RRs) and 95% confidence intervals (Cls) were estimated by Poisson regression. Compared with women never on HT, the RR of endometrial cancer was increased with conjugated estrogen: 4.27 (1.92–9.52), nonconjugated estrogen: 2.00 (1.87–2.13), long cycle combined therapy: 2.89 (2.27–3.67), cyclic combined therapy: 2.06 (1.88–2.27), tibolone 3.56 (2.94–4.32), transdermal estrogen: 2.77 (2.12–3.62) and vaginal estrogen: 1.96 (1.77–2.17), but not with continuous combined therapy: 1.02 (0.87–1.20). In contrast, the risk of Type II tumors appeared decreased with continuous combined therapy: 0.45 (0.20–1.01), and estrogen therapy implied a nonsignificantly altered risk of 1.43 (0.85–2.41). Our findings support that continuous combined therapy is risk free for Type I tumors, while all other hormone therapies increase risk. In contrast, Type II endometrial cancer was less convincingly associated with hormone use, and continuous combined therapy appeared to decrease the risk.
- Open Access
- 19 April 2012
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 175 (12) , 1234-1242
Hormone Therapy and Different Ovarian Cancers: A National Cohort Study
Postmenopausal hormone therapy use increases the risk of ovarian cancer. In the present study, the authors examined the risks of different histologic types of ovarian cancer associated with hormone therapy. Using Danish national registers, the authors identified 909,946 women who were followed from 1995–2005. The women were 50–79 years of age and had no prior hormone-sensitive cancers or bilateral oophorectomy. Hormone therapy prescription data were obtained from the National Register of Medicinal Product Statistics. The National Cancer and Pathology Register provided data on ovarian cancers, including information about tumor histology. The authors performed Poisson regression analyses that included hormone exposures and confounders as time-dependent covariates. In an average of 8.0 years of follow up, 2,681 cases of epithelial ovarian cancer were detected. Compared with never users, women taking unopposed oral estrogen therapy had increased risks of both serous tumors (incidence rate ratio (IRR) = 1.7, 95% confidence interval: 1.4, 2.2) and endometrioid tumors (IRR = 1.5, 95% confidence interval: 1.0, 2.4) but decreased risk of mucinous tumors (IRR = 0.3, 95% confidence interval: 0.1, 0.8). Similar increased risks of serous and endometrioid tumors were found with estrogen/progestin therapy, whereas no association was found with mucinous tumors. Consistent with results from recent cohort studies, the authors found that ovarian cancer risk varied according to tumor histology. The types of ovarian tumors should be given attention in future studies.
- 19 April 2012
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 175 (12) , 1234-1242
Open AccessHormone Therapy and Different Ovarian Cancers: A National Cohort Study
Postmenopausal hormone therapy use increases the risk of ovarian cancer. In the present study, the authors examined the risks of different histologic types of ovarian cancer associated with hormone therapy. Using Danish national registers, the authors identified 909,946 women who were followed from 1995–2005. The women were 50–79 years of age and had no prior hormone-sensitive cancers or bilateral oophorectomy. Hormone therapy prescription data were obtained from the National Register of Medicinal Product Statistics. The National Cancer and Pathology Register provided data on ovarian cancers, including information about tumor histology. The authors performed Poisson regression analyses that included hormone exposures and confounders as time-dependent covariates. In an average of 8.0 years of follow up, 2,681 cases of epithelial ovarian cancer were detected. Compared with never users, women taking unopposed oral estrogen therapy had increased risks of both serous tumors (incidence rate ratio (IRR) = 1.7, 95% confidence interval: 1.4, 2.2) and endometrioid tumors (IRR = 1.5, 95% confidence interval: 1.0, 2.4) but decreased risk of mucinous tumors (IRR = 0.3, 95% confidence interval: 0.1, 0.8). Similar increased risks of serous and endometrioid tumors were found with estrogen/progestin therapy, whereas no association was found with mucinous tumors. Consistent with results from recent cohort studies, the authors found that ovarian cancer risk varied according to tumor histology. The types of ovarian tumors should be given attention in future studies.
- 29 October 2011
- Published by Springer Nature in Cancer Causes & Control
- Vol. 23 (1) , 113-120
Hormone therapy and ovarian borderline tumors: a national cohort study
Little is known about the influence of postmenopausal hormone therapy on the risk of ovarian borderline tumors. We aimed at assessing the influence of different hormone therapies on this risk. A total of 909,875 Danish women 50–79 years old without previous hormone-sensitive cancers or bilateral oophorectomy were followed in this nationwide cohort study 1995–2005. The National Register of Medicinal Product Statistics provided exposure information on all women who redeemed prescriptions on hormone therapy. The National Cancer and Pathology Register provided data on borderline ovarian tumors. Information on confounding factors was available from other national registers. Poisson regression analyses provided risk estimates with hormone exposures as time-dependent covariates. In an average of 8.0 years of follow-up, 703 incident ovarian borderline tumors were detected. Compared with never users, hormone use for more than 4 years increased the risk of borderline tumors: relative risk (RR) 1.40; 95% confidence interval (CI), 1.09–1.81. Combined estrogen and progestin therapy for more than 4 years increased the risk: RR 1.49 (1.10–2.01), with no difference between cyclic and continuous combined therapy (p = 0.83); RR 1.56 (1.08–2.25) and 1.45 (0.87–2.43), respectively. The RR with estrogen therapy did not differ significantly from RR with combined therapy (p = 0.58): RR 1.27 (0.82–1.98). Disregarding the type of hormone therapy, hormone use for 4 years or less did not increase the risk of borderline tumors. Combined hormone therapy for more than 4 years increases the risk of ovarian borderline tumors.
- 29 October 2011
- Published by Springer Nature in Cancer Causes & Control
- Vol. 23 (1) , 113-120
Hormone therapy and ovarian borderline tumors: a national cohort study
Little is known about the influence of postmenopausal hormone therapy on the risk of ovarian borderline tumors. We aimed at assessing the influence of different hormone therapies on this risk. A total of 909,875 Danish women 50–79 years old without previous hormone-sensitive cancers or bilateral oophorectomy were followed in this nationwide cohort study 1995–2005. The National Register of Medicinal Product Statistics provided exposure information on all women who redeemed prescriptions on hormone therapy. The National Cancer and Pathology Register provided data on borderline ovarian tumors. Information on confounding factors was available from other national registers. Poisson regression analyses provided risk estimates with hormone exposures as time-dependent covariates. In an average of 8.0 years of follow-up, 703 incident ovarian borderline tumors were detected. Compared with never users, hormone use for more than 4 years increased the risk of borderline tumors: relative risk (RR) 1.40; 95% confidence interval (CI), 1.09–1.81. Combined estrogen and progestin therapy for more than 4 years increased the risk: RR 1.49 (1.10–2.01), with no difference between cyclic and continuous combined therapy (p = 0.83); RR 1.56 (1.08–2.25) and 1.45 (0.87–2.43), respectively. The RR with estrogen therapy did not differ significantly from RR with combined therapy (p = 0.58): RR 1.27 (0.82–1.98). Disregarding the type of hormone therapy, hormone use for 4 years or less did not increase the risk of borderline tumors. Combined hormone therapy for more than 4 years increases the risk of ovarian borderline tumors.
- Open Access
- 15 July 2009
- Published by American Medical Association (AMA) in JAMA
- Vol. 302 (3) , 298-305
Hormone Therapy and Ovarian Cancer
Primary prevention of ovarian cancer is challenging because little is known about its etiology. A review and meta-analysis of data published between 1966 and 2006 concluded that current use of postmenopausal hormone therapy (HT) increased the risk of ovarian cancer by 30% compared with the absence of HT and suggested that ovarian cancer risk with estrogen therapy (ET) alone was higher than the risk associated with estrogen plus progestin therapy (EPT).1,2 However, the Million Women Study3 with 948 576 women and 2273 incident cases of ovarian cancer found an increased risk of ovarian cancer, but no significant differential effect of ET vs EPT.
- 15 July 2009
- Published by American Medical Association (AMA) in JAMA
- Vol. 302 (3) , 298-305
Open AccessHormone Therapy and Ovarian Cancer
Primary prevention of ovarian cancer is challenging because little is known about its etiology. A review and meta-analysis of data published between 1966 and 2006 concluded that current use of postmenopausal hormone therapy (HT) increased the risk of ovarian cancer by 30% compared with the absence of HT and suggested that ovarian cancer risk with estrogen therapy (ET) alone was higher than the risk associated with estrogen plus progestin therapy (EPT).1,2 However, the Million Women Study3 with 948 576 women and 2273 incident cases of ovarian cancer found an increased risk of ovarian cancer, but no significant differential effect of ET vs EPT.
- 23 May 2007
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 62 (6) , 817-822
Drinking pattern and mortality in Danish nurses
Background/Objective: Subjects and methods: Results: Conclusions:
- 23 May 2007
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 62 (6) , 817-822
Drinking pattern and mortality in Danish nurses
Background/Objective: Subjects and methods: Results: Conclusions:
- Open Access
- 18 April 2007
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 17 (6) , 624-629
Alcohol drinking, consumption patterns and breast cancer among Danish nurses: a cohort study
Background: The aim of this study was to analyse the impact of alcohol intake and drinking pattern on the risk of breast cancer. Methods: A total of 17 647 nurses were followed from 1993 until the end of 2001. At baseline participants completed a questionnaire on alcohol intake and other lifestyle-related factors. Data were analysed using Cox's proportional hazard model. Results: During follow-up 457 women were diagnosed with breast cancer. The relative risk of breast cancer was 2.30 [Confidence interval (CI): 1.56–3.39] for alcohol intake of 22–27 drinks per week, compared to 1–3 drinks per week. Among alcohol consumers, weekly alcohol intake increased the risk of breast cancer with 2% for each additional drink consumed. Weekend consumption increased the risk with 4% for each additional drink consumed friday through sunday. Binge drinking of 4–5 drinks the latest weekday increased risk with 55%, compared with consumption of one drink. A possible threshold in risk estimates was found for consumption above 27 drinks per week. Conclusions: For alcohol consumption above the intake most frequently reported, the risk of breast cancer is increased. The risk is minor for moderate levels but increases for each additional drink consumed during the week. Weekend consumption and binge drinking imply an additional increase in breast cancer risk.
- 18 April 2007
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 17 (6) , 624-629
Open AccessAlcohol drinking, consumption patterns and breast cancer among Danish nurses: a cohort study
Background: The aim of this study was to analyse the impact of alcohol intake and drinking pattern on the risk of breast cancer. Methods: A total of 17 647 nurses were followed from 1993 until the end of 2001. At baseline participants completed a questionnaire on alcohol intake and other lifestyle-related factors. Data were analysed using Cox's proportional hazard model. Results: During follow-up 457 women were diagnosed with breast cancer. The relative risk of breast cancer was 2.30 [Confidence interval (CI): 1.56–3.39] for alcohol intake of 22–27 drinks per week, compared to 1–3 drinks per week. Among alcohol consumers, weekly alcohol intake increased the risk of breast cancer with 2% for each additional drink consumed. Weekend consumption increased the risk with 4% for each additional drink consumed friday through sunday. Binge drinking of 4–5 drinks the latest weekday increased risk with 55%, compared with consumption of one drink. A possible threshold in risk estimates was found for consumption above 27 drinks per week. Conclusions: For alcohol consumption above the intake most frequently reported, the risk of breast cancer is increased. The risk is minor for moderate levels but increases for each additional drink consumed during the week. Weekend consumption and binge drinking imply an additional increase in breast cancer risk.